Brigatinib(Alunbrig)

In 2017, after Takeda Pharmaceutical Company of Japan completed its acquisition of brigatinib (Alunbrig), this prescription drug—which targets ALK, ROS1, IGF-1R, FLT-3 (including wild-type as well as F691L and D835Y mutants), and EGFR—became one of the core products in its oncology pipeline. Patients should strictly follow their doctor's instructions when using it.

Target of Action

Targets of action include anaplastic lymphoma kinase (ALK), ROS1, insulin-like growth factor-1 receptor (IGF-1R), FLT-3 (including wild-type and F691L, D835Y mutants), and EGFR.

Dosage and Administration

Route and frequency of Brigatinib administration: Oral, once daily.

The dosage of Brigatinib should be adjusted according to the patient's actual condition. Please consult your doctor and follow their instructions.

Recommended reading: Dosage and Administration of Brigatinib

Side Effects

Common side effects: Diarrhea, fatigue, nausea, etc.

Serious side effects: Lung problems, hypertension, bradycardia, etc.

Reference article: Side Effects of Brigatinib

Use in Specific Populations

Pregnancy: Brigatinib may cause harm to an unborn baby. Your healthcare provider will determine if you are pregnant before you start treatment with Brigatinib. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Brigatinib.

Breastfeeding: It is not known if Brigatinib passes into your breast milk. Do not breastfeed during treatment with Brigatinib and for 1 week after the last dose.

Daily Precautions

1. Instruct patients to take Brigatinib exactly as prescribed, and not to change the dose or stop treatment unless instructed by a clinician. Instruct patients to swallow Brigatinib tablets whole, with or without food, and not to crush or chew the tablets.

2. If a dose is missed or vomiting occurs after taking a dose, take the next dose at the scheduled time; do not make up the missed dose or take an extra dose to compensate for the vomited dose.

3. Inform patients of the symptoms and risks of serious pulmonary adverse reactions that may occur during Brigatinib treatment, including interstitial lung disease/pneumonia, which are particularly common during the first week of treatment. Instruct patients to immediately inform their clinician if they develop new or worsening pulmonary symptoms (e.g., difficulty breathing or shortness of breath, cough with or without sputum, chest pain, fever), and inform them that these symptoms may be similar to those of lung cancer.

from FDA，2022.02